O	0	7	Heparin	Heparin	NN	B-NP
O	7	8	-	-	HYPH	I-NP
O	8	15	steroid	steroid	NN	I-NP
O	16	26	conjugates	conjugate	NNS	I-NP
O	26	27	:	:	:	O
O	28	31	new	new	JJ	B-NP
O	32	44	angiogenesis	angiogenesis	NN	I-NP
O	45	55	inhibitors	inhibitor	NNS	I-NP
O	56	60	with	with	IN	B-PP
B-Cancer	61	70	antitumor	antitumor	JJ	B-NP
O	71	79	activity	activity	NN	I-NP
O	80	82	in	in	IN	B-PP
O	83	87	mice	mouse	NNS	B-NP
O	87	88	.	.	.	O

O	89	99	Inhibitors	Inhibitor	NNS	B-NP
O	100	102	of	of	IN	B-PP
O	103	115	angiogenesis	angiogenesis	NN	B-NP
O	116	120	hold	hold	VBP	B-VP
O	121	130	potential	potential	NN	B-NP
O	131	133	in	in	IN	B-PP
O	134	137	the	the	DT	B-NP
O	138	147	treatment	treatment	NN	I-NP
O	148	150	of	of	IN	B-PP
B-Cancer	151	157	cancer	cancer	NN	B-NP
O	158	161	and	and	CC	O
O	162	167	other	other	JJ	B-NP
O	168	176	diseases	disease	NNS	I-NP
O	177	182	where	where	WRB	B-ADVP
O	183	186	the	the	DT	B-NP
O	187	194	disease	disease	NN	I-NP
O	195	197	is	be	VBZ	B-VP
O	198	204	caused	cause	VBN	I-VP
O	205	207	or	or	CC	I-VP
O	208	218	maintained	maintain	VBN	I-VP
O	219	221	by	by	IN	B-PP
O	222	225	the	the	DT	B-NP
O	226	239	inappropriate	inappropriate	JJ	I-NP
O	240	246	growth	growth	NN	I-NP
O	247	249	of	of	IN	B-PP
B-Multi-tissue_structure	250	255	blood	blood	NN	B-NP
I-Multi-tissue_structure	256	263	vessels	vessel	NNS	I-NP
O	263	264	.	.	.	O

O	265	267	In	In	IN	B-PP
O	268	271	the	the	DT	B-NP
O	272	279	present	present	JJ	I-NP
O	280	285	study	study	NN	I-NP
O	285	286	,	,	,	O
O	287	288	a	a	DT	B-NP
O	289	294	novel	novel	JJ	I-NP
O	295	304	inhibitor	inhibitor	NN	I-NP
O	305	307	of	of	IN	B-PP
O	308	320	angiogenesis	angiogenesis	NN	B-NP
O	321	324	was	be	VBD	B-VP
O	325	336	synthesized	synthesize	VBN	I-VP
O	337	339	by	by	IN	B-PP
O	340	350	covalently	covalently	RB	B-VP
O	351	358	linking	link	VBG	I-VP
O	359	360	a	a	DT	B-NP
O	361	379	nonanticoagulating	nonanticoagulating	JJ	I-NP
O	380	390	derivative	derivative	NN	I-NP
O	391	393	of	of	IN	B-PP
O	394	401	heparin	heparin	NN	B-NP
O	401	402	,	,	,	O
O	403	410	heparin	heparin	NN	B-NP
O	411	417	adipic	adipic	JJ	I-NP
O	418	427	hydrazide	hydrazide	NN	I-NP
O	428	429	(	(	(	O
O	429	432	HAH	HAH	NN	B-NP
O	432	433	)	)	)	O
O	433	434	,	,	,	O
O	435	437	by	by	IN	B-PP
O	438	440	an	an	DT	B-NP
O	441	445	acid	acid	NN	I-NP
O	445	446	-	-	HYPH	B-NP
O	446	452	labile	labile	JJ	I-NP
O	453	457	bond	bond	NN	I-NP
O	458	460	to	to	TO	B-PP
O	461	464	the	the	DT	B-NP
O	465	479	antiangiogenic	antiangiogenic	JJ	I-NP
O	480	487	steroid	steroid	NN	I-NP
O	487	488	,	,	,	O
O	489	497	cortisol	cortisol	NN	B-NP
O	497	498	.	.	.	O

O	499	502	The	The	DT	B-NP
O	503	512	rationale	rationale	NN	I-NP
O	513	516	was	be	VBD	B-VP
O	517	521	that	that	IN	B-SBAR
O	522	525	the	the	DT	B-NP
O	526	533	heparin	heparin	NN	I-NP
O	534	544	derivative	derivative	NN	I-NP
O	544	545	,	,	,	O
O	546	551	which	which	WDT	B-NP
O	552	557	binds	bind	VBZ	B-VP
O	558	560	to	to	TO	B-PP
O	561	569	sulfated	sulfate	VBN	B-NP
O	570	579	polyanion	polyanion	NN	I-NP
O	580	589	receptors	receptor	NNS	I-NP
O	590	592	on	on	IN	B-PP
B-Cell	593	604	endothelial	endothelial	JJ	B-NP
I-Cell	605	610	cells	cell	NNS	I-NP
O	610	611	,	,	,	O
O	612	618	should	should	MD	B-VP
O	619	630	concentrate	concentrate	VB	I-VP
O	631	634	the	the	DT	B-NP
O	635	642	steroid	steroid	NN	I-NP
O	643	645	on	on	IN	B-PP
O	646	649	the	the	DT	B-NP
B-Cellular_component	650	657	surface	surface	NN	I-NP
O	658	660	of	of	IN	B-PP
B-Cell	661	669	vascular	vascular	JJ	B-NP
I-Cell	670	681	endothelial	endothelial	JJ	I-NP
I-Cell	682	687	cells	cell	NNS	I-NP
O	687	688	.	.	.	O

O	689	700	Endocytosis	Endocytosis	NN	B-NP
O	701	703	of	of	IN	B-PP
O	704	707	the	the	DT	B-NP
O	708	717	conjugate	conjugate	NN	I-NP
O	718	721	and	and	CC	I-NP
O	722	735	decomposition	decomposition	NN	I-NP
O	736	738	of	of	IN	B-PP
O	739	742	the	the	DT	B-NP
O	743	747	acid	acid	NN	I-NP
O	747	748	-	-	HYPH	B-NP
O	748	754	labile	labile	JJ	I-NP
O	755	762	linkage	linkage	NN	I-NP
O	763	769	inside	inside	IN	B-PP
B-Cellular_component	770	779	lysosomes	lysosome	NNS	B-NP
O	780	783	and	and	CC	O
O	784	789	other	other	JJ	B-NP
O	790	796	acidic	acidic	JJ	I-NP
B-Cellular_component	797	810	intracellular	intracellular	JJ	I-NP
I-Cellular_component	811	823	compartments	compartment	NNS	I-NP
O	824	830	should	should	MD	B-VP
O	831	835	then	then	RB	I-VP
O	836	840	lead	lead	VB	I-VP
O	841	843	to	to	TO	B-PP
O	844	851	release	release	NN	B-NP
O	852	854	of	of	IN	B-PP
O	855	858	the	the	DT	B-NP
O	859	867	cortisol	cortisol	NN	I-NP
O	868	871	and	and	CC	I-NP
O	872	882	expression	expression	NN	I-NP
O	883	885	of	of	IN	B-PP
O	886	889	its	its	PRP$	B-NP
O	890	907	antiproliferative	antiproliferative	JJ	I-NP
O	908	916	activity	activity	NN	I-NP
O	916	917	.	.	.	O

O	918	926	Analysis	Analysis	NN	B-NP
O	927	929	of	of	IN	B-PP
O	930	933	the	the	DT	B-NP
O	934	943	stability	stability	NN	I-NP
O	944	946	of	of	IN	B-PP
O	947	950	HAH	HAH	NN	B-NP
O	950	951	-	-	HYPH	B-NP
O	951	959	cortisol	cortisol	NN	I-NP
O	960	966	showed	show	VBD	B-VP
O	967	971	that	that	IN	B-SBAR
O	972	974	it	it	PRP	B-NP
O	975	978	was	be	VBD	B-VP
O	979	985	stable	stable	JJ	B-ADJP
O	986	988	at	at	IN	B-PP
O	989	991	pH	pH	NN	B-NP
O	992	993	7	7	CD	I-NP
O	993	994	.	.	.	O
O	994	995	4	4	CD	B-NP
O	996	999	and	and	CC	O
O	1000	1005	broke	break	VBD	B-VP
O	1006	1010	down	down	RP	B-PRT
O	1011	1018	rapidly	rapidly	RB	B-ADVP
O	1019	1020	(	(	(	O
O	1020	1022	t1	t1	NN	B-NP
O	1022	1023	/	/	SYM	B-NP
O	1023	1024	2	2	CD	I-NP
O	1025	1027	15	15	CD	I-NP
O	1028	1031	min	min	NN	I-NP
O	1031	1032	)	)	)	O
O	1033	1035	at	at	IN	B-PP
O	1036	1038	pH	pH	NN	B-NP
O	1039	1040	4	4	CD	I-NP
O	1040	1041	.	.	.	I-NP
O	1041	1042	8	8	CD	I-NP
O	1043	1045	at	at	IN	B-PP
O	1046	1048	37	37	CD	B-NP
O	1049	1056	degrees	degree	NNS	I-NP
O	1057	1058	C	C	JJ	B-ADJP
O	1058	1059	.	.	.	O

O	1060	1069	Treatment	Treatment	NN	B-NP
O	1070	1072	of	of	IN	B-PP
O	1073	1079	murine	murine	JJ	B-NP
B-Cell	1080	1089	pulmonary	pulmonary	JJ	I-NP
I-Cell	1090	1099	capillary	capillary	JJ	I-NP
I-Cell	1100	1111	endothelial	endothelial	JJ	I-NP
I-Cell	1112	1117	cells	cell	NNS	I-NP
O	1118	1122	with	with	IN	B-PP
O	1123	1126	HAH	HAH	NN	B-NP
O	1126	1127	-	-	HYPH	B-NP
O	1127	1135	cortisol	cortisol	NN	I-NP
O	1136	1138	at	at	IN	B-PP
O	1139	1141	10	10	CD	B-NP
O	1141	1142	(	(	(	O
O	1142	1143	-	-	SYM	O
O	1143	1144	5	5	CD	O
O	1144	1145	)	)	)	O
O	1146	1147	M	M	NN	B-NP
O	1148	1149	(	(	(	O
O	1149	1153	with	with	IN	B-PP
O	1154	1161	respect	respect	NN	B-NP
O	1162	1164	to	to	TO	B-PP
O	1165	1173	cortisol	cortisol	NN	B-NP
O	1173	1174	)	)	)	O
O	1175	1185	suppressed	suppress	VBD	B-VP
O	1186	1191	their	their	PRP$	B-NP
O	1192	1195	DNA	DNA	NN	I-NP
O	1196	1205	synthesis	synthesis	NN	I-NP
O	1206	1208	by	by	IN	B-PP
O	1209	1211	50	50	CD	B-NP
O	1211	1212	%	%	NN	I-NP
O	1213	1216	and	and	CC	O
O	1217	1226	inhibited	inhibit	VBD	B-VP
O	1227	1232	their	their	PRP$	B-NP
O	1233	1242	migration	migration	NN	I-NP
O	1243	1247	into	into	IN	B-PP
B-Pathological_formation	1248	1255	wounded	wounded	JJ	B-NP
I-Pathological_formation	1256	1261	areas	area	NNS	I-NP
O	1262	1264	of	of	IN	B-PP
O	1265	1274	confluent	confluent	JJ	B-NP
B-Cell	1275	1285	monolayers	monolayer	NNS	I-NP
O	1285	1286	.	.	.	O

O	1287	1290	HAH	HAH	NN	B-NP
O	1290	1291	-	-	HYPH	I-NP
O	1291	1299	cortisol	cortisol	NN	I-NP
O	1300	1302	at	at	IN	B-PP
O	1303	1305	10	10	CD	B-NP
O	1305	1306	(	(	(	O
O	1306	1307	-	-	SYM	O
O	1307	1308	4	4	CD	O
O	1308	1309	)	)	)	O
O	1310	1311	M	M	NN	B-NP
O	1312	1313	(	(	(	O
O	1313	1317	with	with	IN	B-PP
O	1318	1325	respect	respect	NN	B-NP
O	1326	1328	to	to	TO	B-PP
O	1329	1337	cortisol	cortisol	NN	B-NP
O	1337	1338	)	)	)	O
O	1339	1342	did	do	VBD	B-VP
O	1343	1346	not	not	RB	I-VP
O	1347	1355	suppress	suppress	VB	I-VP
O	1356	1359	the	the	DT	B-NP
O	1360	1363	DNA	DNA	NN	I-NP
O	1364	1373	synthesis	synthesis	NN	I-NP
O	1374	1376	of	of	IN	B-PP
B-Cell	1377	1382	Lewis	Lewis	NNP	B-NP
I-Cell	1383	1387	lung	lung	NN	I-NP
I-Cell	1388	1397	carcinoma	carcinoma	NN	I-NP
I-Cell	1398	1403	cells	cell	NNS	I-NP
O	1403	1404	.	.	.	O

O	1405	1410	Daily	Daily	JJ	B-NP
O	1411	1412	i	i	NN	I-NP
O	1412	1413	.	.	.	I-NP
O	1413	1414	p	p	NN	I-NP
O	1414	1415	.	.	.	I-NP
O	1416	1426	injections	injection	NNS	I-NP
O	1427	1429	of	of	IN	B-PP
O	1430	1433	HAH	HAH	NN	B-NP
O	1433	1434	-	-	HYPH	B-NP
O	1434	1442	cortisol	cortisol	NN	I-NP
O	1443	1447	into	into	IN	B-PP
O	1448	1452	mice	mouse	NNS	B-NP
O	1453	1460	bearing	bear	VBG	B-VP
O	1461	1462	s	s	NNS	B-NP
O	1462	1463	.	.	.	O
O	1463	1464	c	c	NN	B-NP
O	1464	1465	.	.	.	I-NP
O	1466	1472	sponge	sponge	NN	I-NP
O	1473	1481	implants	implant	NNS	I-NP
O	1482	1490	retarded	retard	VBD	B-VP
O	1491	1506	vascularization	vascularization	NN	B-NP
O	1507	1509	of	of	IN	B-PP
O	1510	1513	the	the	DT	B-NP
O	1514	1520	sponge	sponge	NN	I-NP
O	1520	1521	,	,	,	O
O	1522	1525	and	and	CC	O
O	1526	1536	injections	injection	NNS	B-NP
O	1537	1545	directly	directly	RB	B-ADVP
O	1546	1550	into	into	IN	B-PP
O	1551	1554	the	the	DT	B-NP
O	1555	1561	sponge	sponge	NN	I-NP
O	1562	1571	abolished	abolish	VBD	B-VP
O	1572	1587	vascularization	vascularization	NN	B-NP
O	1588	1591	for	for	IN	B-PP
O	1592	1594	as	as	RB	B-ADVP
O	1595	1599	long	long	RB	I-ADVP
O	1600	1602	as	as	IN	B-SBAR
O	1603	1606	the	the	DT	B-NP
O	1607	1617	injections	injection	NNS	I-NP
O	1618	1622	were	be	VBD	B-VP
O	1623	1632	continued	continue	VBN	I-VP
O	1632	1633	.	.	.	O

O	1634	1639	Daily	Daily	JJ	B-NP
B-Immaterial_anatomical_entity	1640	1641	i	i	NN	I-NP
I-Immaterial_anatomical_entity	1641	1642	.	.	.	I-NP
I-Immaterial_anatomical_entity	1642	1643	v	v	NN	I-NP
I-Immaterial_anatomical_entity	1643	1644	.	.	.	I-NP
O	1645	1655	injections	injection	NNS	I-NP
O	1656	1658	of	of	IN	B-PP
O	1659	1662	HAH	HAH	NN	B-NP
O	1662	1663	-	-	HYPH	B-NP
O	1663	1671	cortisol	cortisol	NN	I-NP
O	1672	1674	at	at	IN	B-PP
O	1675	1680	doses	dose	NNS	B-NP
O	1681	1688	causing	cause	VBG	B-VP
O	1689	1691	no	no	DT	B-NP
O	1692	1700	apparent	apparent	JJ	I-NP
O	1701	1709	toxicity	toxicity	NN	I-NP
O	1710	1718	retarded	retard	VBD	B-VP
O	1719	1722	the	the	DT	B-NP
O	1723	1729	growth	growth	NN	I-NP
O	1730	1732	of	of	IN	B-PP
O	1733	1738	solid	solid	JJ	B-NP
O	1739	1740	s	s	NNS	I-NP
O	1740	1741	.	.	.	B-NP
O	1741	1742	c	c	NN	I-NP
O	1742	1743	.	.	.	O

B-Cancer	1744	1749	Lewis	Lewis	NNP	B-NP
I-Cancer	1750	1754	lung	lung	NN	I-NP
I-Cancer	1755	1765	carcinomas	carcinoma	NNS	I-NP
O	1766	1768	in	in	IN	B-PP
O	1769	1773	mice	mouse	NNS	B-NP
O	1774	1776	by	by	IN	B-PP
O	1777	1779	up	up	RB	B-NP
O	1780	1782	to	to	TO	I-NP
O	1783	1785	65	65	CD	I-NP
O	1785	1786	%	%	NN	I-NP
O	1786	1787	.	.	.	O

O	1788	1790	In	In	IN	B-PP
O	1791	1794	all	all	DT	B-NP
O	1795	1797	of	of	IN	B-PP
O	1798	1803	these	these	DT	B-NP
O	1804	1810	assays	assay	NNS	I-NP
O	1810	1811	,	,	,	O
O	1812	1822	equivalent	equivalent	JJ	B-NP
O	1823	1833	treatments	treatment	NNS	I-NP
O	1834	1838	with	with	IN	B-PP
O	1839	1840	a	a	DT	B-NP
O	1841	1848	mixture	mixture	NN	I-NP
O	1849	1851	of	of	IN	B-PP
O	1852	1855	the	the	DT	B-NP
O	1856	1859	HAH	HAH	NN	I-NP
O	1860	1864	plus	plus	CC	I-NP
O	1865	1873	cortisol	cortisol	NN	I-NP
O	1874	1877	was	be	VBD	B-VP
O	1878	1891	significantly	significantly	RB	B-ADJP
O	1892	1896	less	less	RBR	I-ADJP
O	1897	1906	effective	effective	JJ	I-ADJP
O	1906	1907	.	.	.	O

O	1908	1911	The	The	DT	B-NP
O	1912	1929	antiproliferative	antiproliferative	JJ	I-NP
O	1930	1936	effect	effect	NN	I-NP
O	1937	1939	of	of	IN	B-PP
O	1940	1943	HAH	HAH	NN	B-NP
O	1943	1944	-	-	HYPH	O
O	1944	1952	cortisol	cortisol	NN	B-NP
O	1953	1955	on	on	IN	B-PP
B-Cell	1956	1967	endothelial	endothelial	JJ	B-NP
I-Cell	1968	1973	cells	cell	NNS	I-NP
O	1974	1982	appeared	appear	VBD	B-VP
O	1983	1994	independent	independent	JJ	B-ADJP
O	1995	1997	of	of	IN	B-PP
O	1998	2001	the	the	DT	B-NP
O	2002	2016	glucocorticoid	glucocorticoid	NN	I-NP
O	2017	2025	activity	activity	NN	I-NP
O	2026	2028	of	of	IN	B-PP
O	2029	2032	the	the	DT	B-NP
O	2033	2040	steroid	steroid	NN	I-NP
O	2041	2046	since	since	IN	B-SBAR
O	2047	2050	HAH	HAH	NN	B-NP
O	2051	2061	conjugated	conjugate	VBD	B-VP
O	2062	2064	to	to	TO	B-PP
O	2065	2066	5	5	CD	B-NP
O	2067	2071	beta	beta	SYM	O
O	2071	2072	-	-	HYPH	B-NP
O	2072	2080	pregnane	pregnane	NN	I-NP
O	2080	2081	-	-	HYPH	B-NP
O	2081	2082	3	3	CD	I-NP
O	2083	2088	alpha	alpha	SYM	B-NP
O	2088	2089	,	,	,	O
O	2089	2091	17	17	CD	B-NP
O	2092	2097	alpha	alpha	SYM	B-ADVP
O	2097	2098	,	,	,	O
O	2098	2100	21	21	CD	B-NP
O	2100	2101	-	-	HYPH	I-NP
O	2101	2106	triol	triol	NN	I-NP
O	2106	2107	-	-	HYPH	B-NP
O	2107	2109	20	20	CD	I-NP
O	2109	2110	-	-	HYPH	I-NP
O	2110	2113	one	one	CD	I-NP
O	2113	2114	,	,	,	O
O	2115	2116	a	a	DT	B-NP
O	2117	2124	steroid	steroid	NN	I-NP
O	2125	2132	lacking	lack	VBG	B-VP
O	2133	2147	glucocorticoid	glucocorticoid	NN	B-NP
O	2148	2150	or	or	CC	I-NP
O	2151	2168	mineralocorticoid	mineralocorticoid	NN	I-NP
O	2169	2177	activity	activity	NN	I-NP
O	2177	2178	,	,	,	O
O	2179	2182	was	be	VBD	B-VP
O	2183	2187	even	even	RB	B-ADJP
O	2188	2192	more	more	RBR	I-ADJP
O	2193	2202	effective	effective	JJ	I-ADJP
O	2203	2205	at	at	IN	B-PP
O	2206	2216	inhibiting	inhibit	VBG	B-VP
O	2217	2220	DNA	DNA	NN	B-NP
O	2221	2230	synthesis	synthesis	NN	I-NP
O	2231	2233	by	by	IN	B-PP
O	2234	2240	murine	murine	JJ	B-NP
B-Cell	2241	2250	pulmonary	pulmonary	JJ	I-NP
I-Cell	2251	2260	capillary	capillary	JJ	I-NP
I-Cell	2261	2272	endothelial	endothelial	JJ	I-NP
I-Cell	2273	2278	cells	cell	NNS	I-NP
O	2279	2283	than	than	IN	B-SBAR
O	2284	2287	was	be	VBD	B-VP
O	2288	2291	HAH	HAH	NN	B-NP
O	2291	2292	-	-	HYPH	B-PP
O	2292	2300	cortisol	cortisol	NN	B-NP
O	2300	2301	.	.	.	O

O	2302	2304	In	In	IN	B-PP
O	2305	2315	conclusion	conclusion	NN	B-NP
O	2315	2316	,	,	,	O
O	2317	2320	HAH	HAH	NN	B-NP
O	2320	2321	-	-	HYPH	O
O	2321	2329	cortisol	cortisol	NN	B-NP
O	2330	2340	represents	represent	VBZ	B-VP
O	2341	2344	the	the	DT	B-NP
O	2345	2354	prototype	prototype	NN	I-NP
O	2355	2357	of	of	IN	B-PP
O	2358	2359	a	a	DT	B-NP
O	2360	2363	new	new	JJ	I-NP
O	2364	2369	class	class	NN	I-NP
O	2370	2372	of	of	IN	B-PP
O	2373	2385	angiogenesis	angiogenesis	NN	B-NP
O	2386	2396	inhibitors	inhibitor	NNS	I-NP
O	2397	2400	for	for	IN	B-PP
O	2401	2404	the	the	DT	B-NP
O	2405	2414	treatment	treatment	NN	I-NP
O	2415	2417	of	of	IN	B-PP
B-Cancer	2418	2424	cancer	cancer	NN	B-NP
O	2425	2428	and	and	CC	O
O	2429	2434	other	other	JJ	B-NP
O	2435	2445	angiogenic	angiogenic	JJ	I-NP
O	2446	2454	diseases	disease	NNS	I-NP
O	2454	2455	.	.	.	O

